Company / SG&A Expense
Processa Pharmaceuticals, Inc. SG&A Expense History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.7M
FY2022
5-year range
$945.5K / $4.7M
FY2018-FY2022
Trend
+43.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $945,460 to $5M over the past 6 years.
Based on SEC 10-K filings.
$5M in FY2022.
Increased from $945,460 to $5M over the past 6 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, sg&a expense increased 43.6% year-over-year.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $4.7M | +43.6% |
| FY2021 | $3.3M | +245.3% |
| FY2016 | $945.5K | -53.2% |
| FY2015 | $2.0M | -28.3% |
| FY2014 | $2.8M | +49.6% |
| FY2013 | $1.9M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026